San Diego, California-based ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. Valued at\u00a0$32.1 billion, the company is expected to release its Q3 2026 earnings soon.<\/p>\n
Ahead of the event, analysts expect the company\u2019s\u00a0EPS to be $2.77 on a diluted basis, up 16.9% from $2.37 in the year-ago quarter. The company has exceeded Wall Street\u2019s EPS estimates in each of its last four quarters.<\/p>\n
For fiscal 2026, analysts project the company\u2019s EPS to be $10.98, up 15%\u00a0from $9.55 in fiscal 2025. Moreover, its EPS is expected to rise by roughly 9.1% year over year (YoY) to $11.98 in fiscal 2027.<\/p>\n RMD stock has declined\u00a0marginally over the past 52 weeks, underperforming the S&P 500 Index\u2019s ($SPX) 11.9% rise but slightly rallying the State Street Healthcare Select Sector SPDR ETF\u2019s (XLV)\u00a01.2% decline during the same time frame.<\/p>\n On Jan. 29, RMD stock\u00a0declined marginally following the release of its\u00a0Q2 2026 earnings. The company\u2019s revenue increased 11% from the prior year\u2019s quarter to $1.4 billion and surpassed Wall Street estimates. Moreover, its adjusted EPS for the quarter amounted to $2.81, also topping the Street\u2019s estimates. However, the stock has been exhibiting\u00a0slower-than-average revenue growth compared to its competitors, leading to a loss of investor confidence.<\/p>\n Analysts are moderately bullish on RMD, with the stock having a \u201cModerate Buy\u201d rating overall. Among the 19 analysts covering the stock, eight are recommending a \u201cStrong Buy,\u201d two recommend a \u201cModerate Buy,\u201d eight suggest a \u201cHold,\u201d and one analyst advises \u201cStrong Sell\u201d for the stock. RMD\u2019s average analyst price target is $295.23, indicating an upside of 33.9% from the current levels.<\/p>\n On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on Barchart.com <\/i><\/p>\n<\/p><\/div>\n<\/div>\n<\/div>
<\/div>\n<\/div>